US11116803B2 - Method of treating lung cancer using Parabacteroides goldsteinii - Google Patents

Method of treating lung cancer using Parabacteroides goldsteinii Download PDF

Info

Publication number
US11116803B2
US11116803B2 US16/667,950 US201916667950A US11116803B2 US 11116803 B2 US11116803 B2 US 11116803B2 US 201916667950 A US201916667950 A US 201916667950A US 11116803 B2 US11116803 B2 US 11116803B2
Authority
US
United States
Prior art keywords
lung cancer
parabacteroides goldsteinii
mice
parabacteroides
mts01
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US16/667,950
Other versions
US20200129568A1 (en
Inventor
Po-I Wu
Chih-Jung Chang
Yu-Ling Tsai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Multistars Biotechnology Co Ltd
Original Assignee
Multistars Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TW108138285A external-priority patent/TWI733222B/en
Application filed by Multistars Biotechnology Co Ltd filed Critical Multistars Biotechnology Co Ltd
Priority to US16/667,950 priority Critical patent/US11116803B2/en
Assigned to Multistars Biotechnology Company Limited reassignment Multistars Biotechnology Company Limited ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHANG, CHIH-JUNG, TSAI, YU-LING, WU, PO-I
Publication of US20200129568A1 publication Critical patent/US20200129568A1/en
Application granted granted Critical
Publication of US11116803B2 publication Critical patent/US11116803B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Definitions

  • the present invention relates to a method of using a Parabacteroides goldsteinii for treating lung cancer.
  • Cancer is one of the leading causes of human death today. Although the formation of cancer is still not fully understood, it is believed that carcinogenesis or tumorigenesis can be attributed to cells accumulation of exogenous or endogenous factor leading to genetic abnormalities, and then cause the signal transduction pathways in these cells is erroneous and cell division to be out of control, thereby causing the cells to gradually form cancer. Cancer cells are able to evade apoptosis and have the ability to migrate and invade, so cancer cells proliferate and pass through the lymphatic or vascular system to be transferred metastasize to other parts of the body.
  • Lung cancer can be mainly divided into two types, one is non-small cell lung cancer (NSCLC) and the other is small cell lung cancer (SCLC).
  • NSCLC non-small cell lung cancer
  • SCLC small cell lung cancer
  • Non-small cell lung cancer accounts for about 80% of lung cancer in total.
  • the third most common non-small cell lung cancers in the United States are lung adenocarcinoma/bronchial alveolar carcinoma (35-40%), squamous cell carcinoma (25-30%), and large cell lung cancer (10-15%).
  • Lung cancer is the most easily cured if it is diagnosed at the beginning of the disease. Early cancer means that it has not grown into a large volume or transferred to other parts of the body. The larger or metastatic cancer is more difficult to be treated.
  • the main methods currently used to treat lung cancer include surgery, radiation therapy, chemical drug therapy, target therapy, and combination therapy.
  • the above treatment methods often have side effects; for example, chemical drug treatment could cause nausea and vomiting in patients and infections and bleeding problems in severe one; radiation therapy could also cause nausea and vomiting in patients and hair loss problem in severe one.
  • traditional treatments are often expensive and not affordable for the most patient.
  • those having ordinary skill in the art urgently need to develop a novel pharmaceutical or food product having the efficacy of treating lung cancer for the benefit of a large group of people in need thereof.
  • the objective of the present invention is to provide a method of treating a lung cancer, comprising administering to a subject in need thereof a composition comprising an effective amount of a Parabacteroides goldsteinii.
  • the composition further comprises a metabolite of the Parabacteroides goldsteinii.
  • the Parabacteroides goldsteinii is a live bacterium.
  • the effective amount of the Parabacteroides goldsteinii is at least 1 ⁇ 10 9 CFUs per day.
  • the lung cancer is a non-small cell lung cancer (NSCLC).
  • NSCLC non-small cell lung cancer
  • the non-small cell lung cancer is a Lewis lung carcinoma (LLC).
  • LLC Lewis lung carcinoma
  • the composition increases a survival rate, a mean survival time and a body weight of the subject with the lung cancer, and inhibits a growth of a lung tumor.
  • the inhibiting step comprises inhibiting the growth of the lung tumor at different time points.
  • the composition further comprises other bacteria.
  • the Parabacteroides goldsteinii is Parabacteroides goldsteinii DSM32939.
  • the composition is a pharmaceutical composition or a food product.
  • the composition further comprises a pharmaceutically acceptable excipient, carrier, adjuvant, or food additive.
  • the composition is in the form of a spray, a solution, a semi-solid state, a solid state, a gelatin capsule, a soft capsule, a tablet, an oral strip, a chewing gum or a freeze-dried powder preparation.
  • the effect of the Parabacteroides goldsteinii of the present invention is that the effect of treating lung cancer which is achieved by increasing the survival rate, the mean survival time, and the body weight of the subjects with lung cancer, and inhibiting the growth of the lung tumor.
  • FIG. 1 shows that the effect of the Parabacteroides goldsteinii MTS01 on increasing the survival rate of lung cancer mice.
  • FIG. 2 shows that the effect of the Parabacteroides goldsteinii MTS01 on increasing the mean survival time of lung cancer mice.
  • FIG. 3 shows that the effect of the Parabacteroides goldsteinii MTS01 on increasing the body weight of lung cancer mice. *p ⁇ 0.05; ***p ⁇ 0.001; NS means no significant difference.
  • FIG. 4 shows that the appearance of the effect of the Parabacteroides goldsteinii MTS01 on inhibiting the growth of the lung tumor.
  • FIG. 5 shows that the H&F stained images of the effect of the Parabacteroides goldsteinii MTS01 on inhibiting the growth of the lung tumor.
  • FIG. 6 shows that the effect of the Parabacteroides goldsteinii MTS01 on inhibiting the growth of the lung tumor. **p ⁇ 0.01; ***p ⁇ 0.001.
  • FIG. 7 shows that the bioluminescence images in vivo effect of Parabacteroides goldsteinii MTS01 on inhibiting lung cancer after Lewis Lung Carcinoma cells (LLC) implanted on the 7th day.
  • LLC Lewis Lung Carcinoma cells
  • FIG. 8 shows that the bioluminescence images in vivo effect of Parabacteroides goldsteinii MTS01 on inhibiting lung cancer after Lewis Lung Carcinoma cells (LLC) implanted on the 14th day.
  • FIG. 9 shows that the bioluminescence images in vivo effect of Parabacteroides goldsteinii MTS01 on inhibiting lung cancer after Lewis Lung Carcinoma cells (LLC) implanted on the 21st day.
  • LLC Lewis Lung Carcinoma cells
  • FIG. 10 shows that the in vivo effect of the Parabacteroides goldsteinii MTS01 on inhibiting lung cancer at different time points. ***p ⁇ 0.001.
  • the Parabacteroides goldsteinii is a Gram-negative, particularly anaerobic non-spore forming and non-moving bacterium, and is also a probiotic bacterium.
  • the probiotic or probiotic bacteria is a microorganism, the cells thereof, the mixed strains, the extracts or the metabolites with a positive effect on the host itself, usually derived from the human body and beneficial to intestinal health.
  • Probiotic or probiotic bacteria can also refer to certain microorganisms that are externally supplemented and are beneficial to the body.
  • the metabolite of the probiotic or probiotic bacteria is a substance which is secreted into the bacterial culture solution after being metabolized by the bacteria.
  • the operating procedures and parameter conditions for bacterial culture are within the professional literacy and routine techniques of those having ordinary skill in the art.
  • the “effective amount” describes herein is the amount of the Parabacteroides goldsteinii requires for direct treatment of individuals with lung cancer.
  • the effective amount varies depending on the species or individual being treated, but the effective amount can be determined experimentally by, for example, a dose escalation test.
  • the “the bacterial component thereof” describes herein is a derivative substance directly or indirectly related to the bacterium when it is cultured, including but not limited to the metabolic product of the bacterium, the structure of the bacterium, the bacteria-related activity and the inactive ingredient, etc.
  • Parabacteroides goldsteinii describes herein is intended to encompass those of the Parabacteroides goldsteinii , which is readily available to those having ordinary skill in the art, for example, the Parabacteroides goldsteinii purchased from domestic or foreign depository institutions, and a strain of Parabacteroides goldsteinii isolated and purified from a natural source using a microorganism separation method conventionally used in the art.
  • the “treating” or “treatment” describes herein means alleviating, reducing, ameliorating, relieving, or controlling a disease or one or more clinical signs of a disorder, and lowering, stopping, or reversing the progress of the severity of a condition or a symptom being treated.
  • the pharmaceutical composition can be manufactured into a dosage form suitable for parenterally or orally administration using techniques well known to those having skill in the art, including, but not limited to, an injection, for example, sterile aqueous solutions or dispersions, a sterile powder, tablets, a tablet, a lozenge, a pill, a capsule, a dispersible powder or a granule, a solution, a suspension, a emulsion, a syrup, an elixir, a slurry and the like.
  • an injection for example, sterile aqueous solutions or dispersions, a sterile powder, tablets, a tablet, a lozenge, a pill, a capsule, a dispersible powder or a granule, a solution, a suspension, a emulsion, a syrup, an elixir, a slurry and the like.
  • the pharmaceutical composition can be administered by a parenteral route selected from the group consisting of the intraperitoneal injection, the subcutaneous injection, the intramuscular injection, and the intravenous injection.
  • the pharmaceutical composition could further comprise a pharmaceutically acceptable carrier that is widely used in pharmaceutical manufacturing techniques.
  • the pharmaceutically acceptable carrier can comprise one or more agents selected from the group consisting of a solvent, an emulsifier, a suspending agent, a decomposer, a binding agent, an excipient, a stabilizing agent, a chelating agent, a diluent, a gelling agent, a preservative, a lubricant, an absorption delaying agent, a liposome, and the like.
  • the pharmaceutically acceptable carrier can comprise one or more agents selected from the group consisting of a solvent, an emulsifier, a suspending agent, a decomposer, a binding agent, an excipient, a stabilizing agent, a chelating agent, a diluent, a gelling agent, a preservative, a lubricant, an absorption delaying agent, a liposome, and the like.
  • the pharmaceutically acceptable carrier comprises a solvent selected from the group consisting of water, normal saline, phosphate buffered saline (PBS), sugary solution, aqueous solution containing alcohol, and combinations thereof.
  • a solvent selected from the group consisting of water, normal saline, phosphate buffered saline (PBS), sugary solution, aqueous solution containing alcohol, and combinations thereof.
  • the pharmaceutical composition can be used as a food additive, added by the conventional method in the preparation of the raw material, or added during the production of the food, and matched with any edible material to be made into food products for human and non-human animals.
  • the types of the food products include, but are not limited to, beverages, fermented foods, bakery products, health foods, and dietary supplements.
  • the use of the Parabacteroides goldsteinii of the present invention in the treatment of lung cancer can be, but is not limited to, oral administration to the subject in need thereof.
  • the composition can be orally administered along with food; therefore, the preparation of the composition comprising the Parabacteroides goldsteinii of the present invention can further include a protein, a monosaccharide, a disaccharide, an oligosaccharide, an oligosaccharide, a polysaccharide, a carbohydrate, an amino acid, a lipid, a vitamin, or any combination well-known in the art.
  • the preparation of the composition comprising the Parabacteroides goldsteinii of the present invention can further include a pharmaceutically acceptable excipient, carrier, adjuvant, or food additive.
  • the composition is in the form of, but is not limited to a spray gas, a solution, a semi-solid state, a solid, a gelatin capsule, a soft capsule, a tablet, a lozenge, a chewing gum, and/or a freeze-dried powder preparation.
  • the Parabacteroides goldsteinii of the present invention or the composition containing other ingredients can further use in the preparation of a food, a health food, a dietary supplement, or a vaccine composition.
  • C57BL/6J male mice were purchased from National Applied Research Laboratories, NARLab, Taiwan. All mice were fed ad libitum with chow and water. Animals were housed in a temperature-controlled room (19-23° C.) under a 12 hours dark-light cycle. Animals were housed in a specific pathogen-free facility and were treated in accordance with guidelines from the National Institutes of Health (USA). In the following experiments, C57BL/6J male mice were injected with Lewis Lung Carcinoma (LLC) cells (1 ⁇ 10 6 cells) in the tail vein, and then the growth and volume of the tumor were monitored throughout the experiment.
  • LLC Lewis Lung Carcinoma
  • the Parabacteroides goldsteinii (hereinafter referred to as P. goldsteinii ) MTS01 used in the example of the present invention is a kind of probiotic bacteria, which can or treat lung cancer, and is deposited in Deutsche Sammlung von Mikroorganismen and Zellkulturen (DSMZ; Inhoffenstr. 7B, D-38124 Braunschweig, Germany) on Oct. 29, 2018, and the number is DSM 32939.
  • the Parabacteroides goldsteinii is an obligate anaerobe that needs to be cultured in an anaerobic incubator at 37° C. for about 48 hours, wherein the culturing system contains 10% CO 2 , 10% H 2 , and 80% N 2 .
  • the Parabacteroides distasonis (hereinafter referred to as P. distasonis ) used in the example of the present invention was purchased from American Type Culture Collection, and the number is ATCC 8503.
  • YCFA medium was used for culturing, wherein the Parabacteroides distasonis was cultured in 50 mL YCFA at 37° C. in an anaerobic incubator for 24 hr.
  • the cell suspension for oral administration was prepared by suspending the cultured bacterial cells in oxygen-free PBS with a final cell density of 1 ⁇ 10 9 CFU. 100 ⁇ L of the suspension solution was given daily.
  • the non-small cell lung cancer, NSCLC, used in the example of the present invention is Lewis lung cancer (LLC) cells (purchased from ATCC, and the number is ATCC®CRL 1642TM).
  • LLC cells were maintained in Dulbecco's modified Eagle's medium, DMEM, (purchased from Gibco, USA) supplemented with 10% fetal bovine serum (purchased from Gibco, USA), 100 U/mL of penicillin, and 100 ⁇ g/mL of streptomycin, and were incubated at 37° C. in a humidified atmosphere containing 5% CO 2 .
  • mice in the normal control group were treated with sterile drinking water and fed with PBS oral gavage once per day for 3 weeks; the mice in the pathological control group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1 ⁇ 10 6 ) intravenous injection via tail vein and fed with PBS by oral gavage once per day during the entire period of experiment; the mice in the experimental group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1 ⁇ 10 6 ) intravenous injection via tail vein and treated with Parabacteroides goldsteinii MTS01 (1 ⁇ 10 9 CFU) once per day by oral gavage during the entire period of experiment; the mice in the comparison group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1 ⁇ 10 6 ) intravenous injection via tail vein and treated with Parabacteroides distasonis (1 ⁇ 10 9 CFU) once per day by oral gavage during the entire period of experiment.
  • the results of this example were represented by three independent experiments
  • FIG. 1 The results of the effect of the Parabacteroides goldsteinii MTS01 on increasing the survival rate of lung cancer mice were shown in FIG. 1 .
  • the survival rate of the mice in the pathological control group was 20%, and the survival rate of the mice in the experimental group was 50%, which was higher than that of the mice in the comparison group.
  • the mice in the normal control were healthy and alive throughout the experiment.
  • the results indicate that the Parabacteroides goldsteinii strain MTS01 of the present invention can increase the survival rate of mice with lung cancer.
  • the experimental animals, the Parabacteroides goldsteinii , the Parabacteroides distasonis , and the type and the culturing method of the Lewis lung cancer were the same as those described in example 1.
  • mice in the normal control group were treated with sterile drinking water and fed with PBS oral gavage once per day for 4 weeks; the mice in the pathological control group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1 ⁇ 10 6 ) intravenous injection via tail vein and fed with PBS by oral gavage once per day during the entire period of experiment; the mice in the experimental group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1 ⁇ 10 6 ) intravenous injection via tail vein and treated with Parabacteroides goldsteinii MTS01 (1 ⁇ 10 9 CFU) once per day by oral gavage during the entire period of experiment; the mice in the comparison group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1 ⁇ 10 6 ) intravenous injection via tail vein and treated with Parabacteroides distasonis (1 ⁇ 10 9 CFU) once per day by oral gavage during the entire period of experiment.
  • the results of this example were represented by three independent experiments
  • mice in the experimental group were 22.6 days, which was higher than that of the mice in the pathological control group (19.3 days) (P ⁇ 0.01) and that of the mice in the comparison group.
  • the mice in the normal control were healthy and alive throughout the experiment.
  • the results indicate that the Parabacteroides goldsteinii strain MTS01 of the present invention can increase the mean survival time of mice with lung cancer.
  • the experimental animals, the Parabacteroides goldsteinii , the Parabacteroides distasonis , and the type and the culturing method of the Lewis lung cancer were the same as those described in example 1.
  • mice in the normal control group were treated with sterile drinking water and fed with PBS oral gavage once per day for 4 weeks; the mice in the pathological control group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1 ⁇ 10 6 ) intravenous injection via tail vein and fed with PBS by oral gavage once per day during the entire period of experiment; the mice in the experimental group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1 ⁇ 10 6 ) intravenous injection via tail vein and treated with Parabacteroides goldsteinii MTS01 (1 ⁇ 10 9 CFU) once per day by oral gavage during the entire period of experiment; the mice in the comparison group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1 ⁇ 10 6 ) intravenous injection via tail vein and treated with Parabacteroides distasonis (1 ⁇ 10 9 CFU) once per day by oral gavage during the entire period of experiment.
  • mice in the pathological control group were significantly lower than that of the mice in the normal control group.
  • the body weight gain of the mice in the experimental group mice was significantly increased with the simultaneously fed with the Parabacteroides goldsteinii MTS01 of the present invention, whereas the mice in the comparison group did not show this phenomenon.
  • the results indicate that the Parabacteroides goldsteinii strain MTS01 of the present invention can effectively improve the body weight loss in the subjects caused by LLC.
  • the experimental animals, the Parabacteroides goldsteinii , the Parabacteroides distasonis , and the type and the culturing method of the Lewis lung cancer were the same as those described in example 1.
  • mice in the normal control group were treated with sterile drinking water and fed with PBS oral gavage once per day for 3 weeks; the mice in the pathological control group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1 ⁇ 10 6 ) intravenous injection via tail vein and fed with PBS by oral gavage once per day during the entire period of experiment; the mice in the experimental group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1 ⁇ 10 6 ) intravenous injection via tail vein and treated with Parabacteroides goldsteinii MTS01 (1 ⁇ 10 9 CFU) once per day by oral gavage during the entire period of experiment; the mice in the comparison group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1 ⁇ 10 6 ) intravenous injection via tail vein and treated with Parabacteroides distasonis (1 ⁇ 10 9 CFU) once per day by oral gavage during the entire period of experiment.
  • the results of this example were represented by three independent experiments
  • mice After fed with the Parabacteroides distasonis MTS01 by oral gavage for 21 days, each group of mice was sacrificed, and the lungs were removed and the appearance of the lungs was observed. The results of the experiment were shown in FIG. 4 .
  • FIG. 4 The appearance results of the effect of the Parabacteroides goldsteinii MTS01 on inhibiting the growth of the lung tumor were shown in FIG. 4 .
  • the solid tumors (as indicated by the arrows) were spotted on multiple sites in the group bearing with LLC.
  • the number of lung tumors in the mice of the experimental group was significantly reduced, while the comparison group did not show the phenomena.
  • the results indicate that the Parabacteroides goldsteinii strain MTS01 of the present invention can inhibit the growth of lung tumor.
  • the lung leaves of the mice in the normal control group (CTL), the pathological control group (LLC), and the experimental group (LLC+ P. goldsteinii MTS01) were fixed in 10% neutral-buffered formalin, and then embedded in paraffin and thin sections with a thickness of 4 mm were prepared and stained with hematoxylin and eosin (H&E). Thereafter, the stained lungs were histologically examined using a slide scanner and the entire lung lobe was photographed (Olympus VS120). Representative images of whole slide scan and 500 ⁇ m or 250 ⁇ m optical zoom using H&E-stained lung sections. The results of the experiment were shown in FIG. 5 .
  • the H&E stained results of the effect of the Parabacteroides goldsteinii MTS01 on inhibiting the growth of the lung tumor were shown in FIG. 5 .
  • the number of lung tumors in the mice of the pathological control group was significantly increased.
  • the number of lung tumors in the mice of the experimental group was significantly reduced.
  • the results indicate that the Parabacteroides goldsteinii strain MTS01 of the present invention can inhibit the growth of lung tumor.
  • FIG. 6 The data results of the effect of the Parabacteroides goldsteinii MTS01 on inhibiting the growth of the lung tumor were shown in FIG. 6 .
  • the lung tumor weight of the mice in the pathological control group was significantly increased.
  • the lung tumor weight of the mice in the experimental group was significantly reduced.
  • the results indicate that the Parabacteroides goldsteinii MTS01 of the present invention can inhibit the growth of the tumor growth in the mouse model with lung tumors.
  • the experimental animals, the Parabacteroides goldsteinii , the Parabacteroides distasonis , and the type and the culturing method of the Lewis lung cancer were the same as those described in example 1.
  • CTL normal control group
  • LLC pathological control group
  • LLC+Pg MTS01 the mice in the normal control group were treated with sterile drinking water and fed with PBS oral gavage once per day;
  • the mice in the pathological control group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1 ⁇ 10 6 ) intravenous injection via tail vein and fed with PBS by oral gavage once per day during the entire period of experiment;
  • the mice in the experimental group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1 ⁇ 10 6 ) intravenous injection via tail vein and treated with Parabacteroides goldsteinii MTS01 (1 ⁇ 10 9 CFU) once per day by oral gavage during the entire period of experiment.
  • mice of each group were anesthetized with isoflurane and intraperitoneally injected with firefly D-luciferin (15 mg/mL in PBS; Gold Biotechnology), and then were imaged with a cooled charge-coupled device (CCD) camera (IVIS; PerkinElmer) after 7 minutes.
  • CCD charge-coupled device
  • IVIS IVIS Lumina XR Imaging system
  • the luciferin dose was 150 mg/kg.
  • the results of the example were shown in FIG. 7 to FIG. 10 .
  • the scale indicates luminescent intensity in terms of radiant efficiency.
  • the bioluminescence imaging results of in vivo effect of Parabacteroides goldsteinii MTS01 on inhibiting lung cancer after LLC cells implanted on the 7th day were shown in FIG. 7 .
  • the luminescent intensity measured from the mice in the pathological control group was significantly increased.
  • the luminescent intensity measured from the mice in the experimental group was significantly reduced.
  • the results indicate that the Parabacteroides goldsteinii MTS01 of the present invention has an effect of inhibiting lung cancer after LLC cells implanted on the 7th day in vivo.
  • FIG. 8 The bioluminescence imaging results of in vivo effect of Parabacteroides goldsteinii MTS01 on inhibiting lung cancer after LLC cells implanted on the 14th day were shown in FIG. 8 .
  • the luminescent intensity measured from the mice in the pathological control group was significantly increased.
  • the luminescent intensity measured from the mice in the experimental group was significantly reduced.
  • the results indicate that the Parabacteroides goldsteinii MTS01 of the present invention has an effect of inhibiting lung cancer after LLC cells implanted on the 14th day in vivo.
  • the bioluminescence imaging results of in vivo effect of Parabacteroides goldsteinii MTS01 on inhibiting lung cancer after LLC cells implanted on the 21st day were shown in FIG. 9 .
  • the luminescent intensity measured from the mice in the pathological control group was significantly increased.
  • the luminescent intensity measured from the mice in the experimental group was significantly reduced.
  • the results indicate that the Parabacteroides goldsteinii MTS01 of the present invention has an effect of inhibiting lung cancer after LLC cells implanted on the 21st day in vivo.
  • the results of in vivo effect of the Parabacteroides goldsteinii MTS01 on inhibiting lung cancer at different time points were shown in FIG. 10 .
  • the luminescent intensity measured from the mice in the pathological control group increased significantly as the time of LLC cells implantation.
  • the luminescent intensity measured from the mice in the experimental group increased as the time of LLC cells implantation, but the increase range was significantly reduced.
  • the results indicate that the Parabacteroides goldsteinii MTS01 of the present invention has an effect of inhibiting lung cancer at different time points in vivo.
  • the effect of the Parabacteroides goldsteinii of the present invention is that the effect of treating lung cancer which is achieved by increasing the survival rate, the mean survival time, and the body weight of the subjects with lung cancer, and inhibiting the growth of the lung tumor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present disclosure provides a use of Parabacteroides goldsteinii for treating lung cancer.

Description

CROSS-REFERENCE TO RELATED APPLICATION
This application claims priority of U.S. provisional application No. 62/753,112, filed on Oct. 31, 2018, and priority of Taiwan patent application No. 108138285, filed on Oct. 23, 2019 the content of which are incorporated herein in its entirety by reference.
BACKGROUND OF THE INVENTION 1. Field of the Invention
The present invention relates to a method of using a Parabacteroides goldsteinii for treating lung cancer.
2. The Prior Art
Cancer is one of the leading causes of human death today. Although the formation of cancer is still not fully understood, it is believed that carcinogenesis or tumorigenesis can be attributed to cells accumulation of exogenous or endogenous factor leading to genetic abnormalities, and then cause the signal transduction pathways in these cells is erroneous and cell division to be out of control, thereby causing the cells to gradually form cancer. Cancer cells are able to evade apoptosis and have the ability to migrate and invade, so cancer cells proliferate and pass through the lymphatic or vascular system to be transferred metastasize to other parts of the body.
Lung cancer can be mainly divided into two types, one is non-small cell lung cancer (NSCLC) and the other is small cell lung cancer (SCLC). Non-small cell lung cancer accounts for about 80% of lung cancer in total. The third most common non-small cell lung cancers in the United States are lung adenocarcinoma/bronchial alveolar carcinoma (35-40%), squamous cell carcinoma (25-30%), and large cell lung cancer (10-15%). Lung cancer is the most easily cured if it is diagnosed at the beginning of the disease. Early cancer means that it has not grown into a large volume or transferred to other parts of the body. The larger or metastatic cancer is more difficult to be treated.
The main methods currently used to treat lung cancer include surgery, radiation therapy, chemical drug therapy, target therapy, and combination therapy. However, the above treatment methods often have side effects; for example, chemical drug treatment could cause nausea and vomiting in patients and infections and bleeding problems in severe one; radiation therapy could also cause nausea and vomiting in patients and hair loss problem in severe one. In addition, traditional treatments are often expensive and not affordable for the most patient. In order to solve the above problems, those having ordinary skill in the art urgently need to develop a novel pharmaceutical or food product having the efficacy of treating lung cancer for the benefit of a large group of people in need thereof.
SUMMARY OF THE INVENTION
To solve the foregoing problem, the objective of the present invention is to provide a method of treating a lung cancer, comprising administering to a subject in need thereof a composition comprising an effective amount of a Parabacteroides goldsteinii.
In one embodiment of the present invention, the composition further comprises a metabolite of the Parabacteroides goldsteinii.
In one embodiment of the present invention, the Parabacteroides goldsteinii is a live bacterium.
In one embodiment of the present invention, the effective amount of the Parabacteroides goldsteinii is at least 1×109 CFUs per day.
In one embodiment of the present invention, the lung cancer is a non-small cell lung cancer (NSCLC).
In one embodiment of the present invention, the non-small cell lung cancer is a Lewis lung carcinoma (LLC).
In one embodiment of the present invention, the composition increases a survival rate, a mean survival time and a body weight of the subject with the lung cancer, and inhibits a growth of a lung tumor.
In one embodiment of the present invention, the inhibiting step comprises inhibiting the growth of the lung tumor at different time points.
In one embodiment of the present invention, the composition further comprises other bacteria.
In one embodiment of the present invention, the Parabacteroides goldsteinii is Parabacteroides goldsteinii DSM32939.
In one embodiment of the present invention, the composition is a pharmaceutical composition or a food product.
In one embodiment of the present invention, the composition further comprises a pharmaceutically acceptable excipient, carrier, adjuvant, or food additive.
In one embodiment of the present invention, the composition is in the form of a spray, a solution, a semi-solid state, a solid state, a gelatin capsule, a soft capsule, a tablet, an oral strip, a chewing gum or a freeze-dried powder preparation.
In summary, the effect of the Parabacteroides goldsteinii of the present invention is that the effect of treating lung cancer which is achieved by increasing the survival rate, the mean survival time, and the body weight of the subjects with lung cancer, and inhibiting the growth of the lung tumor.
The embodiments of the present invention are further described with the following drawings. The following embodiments are given to illustrate the present invention and are not intended to limit the scope of the present invention, and those having ordinary skill in the art can make some modifications and refinements without departing from the spirit and scope of the present invention. Therefore, the scope of the present invention is defined by the scope of the appended claims.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows that the effect of the Parabacteroides goldsteinii MTS01 on increasing the survival rate of lung cancer mice.
FIG. 2 shows that the effect of the Parabacteroides goldsteinii MTS01 on increasing the mean survival time of lung cancer mice.
FIG. 3 shows that the effect of the Parabacteroides goldsteinii MTS01 on increasing the body weight of lung cancer mice. *p<0.05; ***p<0.001; NS means no significant difference.
FIG. 4 shows that the appearance of the effect of the Parabacteroides goldsteinii MTS01 on inhibiting the growth of the lung tumor.
FIG. 5 shows that the H&F stained images of the effect of the Parabacteroides goldsteinii MTS01 on inhibiting the growth of the lung tumor.
FIG. 6 shows that the effect of the Parabacteroides goldsteinii MTS01 on inhibiting the growth of the lung tumor. **p<0.01; ***p<0.001.
FIG. 7 shows that the bioluminescence images in vivo effect of Parabacteroides goldsteinii MTS01 on inhibiting lung cancer after Lewis Lung Carcinoma cells (LLC) implanted on the 7th day.
FIG. 8 shows that the bioluminescence images in vivo effect of Parabacteroides goldsteinii MTS01 on inhibiting lung cancer after Lewis Lung Carcinoma cells (LLC) implanted on the 14th day.
FIG. 9 shows that the bioluminescence images in vivo effect of Parabacteroides goldsteinii MTS01 on inhibiting lung cancer after Lewis Lung Carcinoma cells (LLC) implanted on the 21st day.
FIG. 10 shows that the in vivo effect of the Parabacteroides goldsteinii MTS01 on inhibiting lung cancer at different time points. ***p<0.001.
 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT Definition
The data provides in the present invention represent approximated, experimental values that vary within a range of ±20%, preferably ±10%, and most preferably ±5%.
Statistical analysis is performed using GraphPad prism 5.01 software (GraphPad Software Inc., San Diego, Calif.). Data are expressed as mean±standard deviation (SD), and differences between groups are statistically analyzed by one-way ANOVA and statistical analysis is performed by Dunnett's multiple comparison test.
According to the present invention, the Parabacteroides goldsteinii is a Gram-negative, particularly anaerobic non-spore forming and non-moving bacterium, and is also a probiotic bacterium.
According to the present invention, the probiotic or probiotic bacteria is a microorganism, the cells thereof, the mixed strains, the extracts or the metabolites with a positive effect on the host itself, usually derived from the human body and beneficial to intestinal health. Probiotic or probiotic bacteria can also refer to certain microorganisms that are externally supplemented and are beneficial to the body. Wherein, the metabolite of the probiotic or probiotic bacteria is a substance which is secreted into the bacterial culture solution after being metabolized by the bacteria.
According to the present invention, the operating procedures and parameter conditions for bacterial culture are within the professional literacy and routine techniques of those having ordinary skill in the art.
The “effective amount” describes herein is the amount of the Parabacteroides goldsteinii requires for direct treatment of individuals with lung cancer. The effective amount varies depending on the species or individual being treated, but the effective amount can be determined experimentally by, for example, a dose escalation test.
The “metabolite” describes herein is a substance which is secreted into the bacterial culture solution after being metabolized by the bacteria.
The “the bacterial component thereof” describes herein is a derivative substance directly or indirectly related to the bacterium when it is cultured, including but not limited to the metabolic product of the bacterium, the structure of the bacterium, the bacteria-related activity and the inactive ingredient, etc.
The “Parabacteroides goldsteinii” describes herein is intended to encompass those of the Parabacteroides goldsteinii, which is readily available to those having ordinary skill in the art, for example, the Parabacteroides goldsteinii purchased from domestic or foreign depository institutions, and a strain of Parabacteroides goldsteinii isolated and purified from a natural source using a microorganism separation method conventionally used in the art.
The “treating” or “treatment” describes herein means alleviating, reducing, ameliorating, relieving, or controlling a disease or one or more clinical signs of a disorder, and lowering, stopping, or reversing the progress of the severity of a condition or a symptom being treated.
According to the present invention, the pharmaceutical composition can be manufactured into a dosage form suitable for parenterally or orally administration using techniques well known to those having skill in the art, including, but not limited to, an injection, for example, sterile aqueous solutions or dispersions, a sterile powder, tablets, a tablet, a lozenge, a pill, a capsule, a dispersible powder or a granule, a solution, a suspension, a emulsion, a syrup, an elixir, a slurry and the like.
According to the present invention, the pharmaceutical composition can be administered by a parenteral route selected from the group consisting of the intraperitoneal injection, the subcutaneous injection, the intramuscular injection, and the intravenous injection.
According to the present invention, the pharmaceutical composition could further comprise a pharmaceutically acceptable carrier that is widely used in pharmaceutical manufacturing techniques. For example, the pharmaceutically acceptable carrier can comprise one or more agents selected from the group consisting of a solvent, an emulsifier, a suspending agent, a decomposer, a binding agent, an excipient, a stabilizing agent, a chelating agent, a diluent, a gelling agent, a preservative, a lubricant, an absorption delaying agent, a liposome, and the like. The selection and quantity of these reagents falls within the professional literacy and routine skills of those having ordinary skill in the art.
According to the present invention, the pharmaceutically acceptable carrier comprises a solvent selected from the group consisting of water, normal saline, phosphate buffered saline (PBS), sugary solution, aqueous solution containing alcohol, and combinations thereof.
According to the present invention, the pharmaceutical composition can be used as a food additive, added by the conventional method in the preparation of the raw material, or added during the production of the food, and matched with any edible material to be made into food products for human and non-human animals.
According to the present invention, the types of the food products include, but are not limited to, beverages, fermented foods, bakery products, health foods, and dietary supplements.
The use of the Parabacteroides goldsteinii of the present invention in the treatment of lung cancer can be, but is not limited to, oral administration to the subject in need thereof. The composition can be orally administered along with food; therefore, the preparation of the composition comprising the Parabacteroides goldsteinii of the present invention can further include a protein, a monosaccharide, a disaccharide, an oligosaccharide, an oligosaccharide, a polysaccharide, a carbohydrate, an amino acid, a lipid, a vitamin, or any combination well-known in the art.
Otherwise, the preparation of the composition comprising the Parabacteroides goldsteinii of the present invention can further include a pharmaceutically acceptable excipient, carrier, adjuvant, or food additive. The composition is in the form of, but is not limited to a spray gas, a solution, a semi-solid state, a solid, a gelatin capsule, a soft capsule, a tablet, a lozenge, a chewing gum, and/or a freeze-dried powder preparation. Simultaneously, the Parabacteroides goldsteinii of the present invention or the composition containing other ingredients can further use in the preparation of a food, a health food, a dietary supplement, or a vaccine composition.
Example 1
Effect of Parabacteroides goldsteinii MTS01 on Increasing the Survival Rate of Lung Cancer Mice
In the embodiment of the present invention, six-to-eight-week-old, specific pathogen-free, C57BL/6J male mice were purchased from National Applied Research Laboratories, NARLab, Taiwan. All mice were fed ad libitum with chow and water. Animals were housed in a temperature-controlled room (19-23° C.) under a 12 hours dark-light cycle. Animals were housed in a specific pathogen-free facility and were treated in accordance with guidelines from the National Institutes of Health (USA). In the following experiments, C57BL/6J male mice were injected with Lewis Lung Carcinoma (LLC) cells (1×106 cells) in the tail vein, and then the growth and volume of the tumor were monitored throughout the experiment.
The Parabacteroides goldsteinii (hereinafter referred to as P. goldsteinii) MTS01 used in the example of the present invention is a kind of probiotic bacteria, which can or treat lung cancer, and is deposited in Deutsche Sammlung von Mikroorganismen and Zellkulturen (DSMZ; Inhoffenstr. 7B, D-38124 Braunschweig, Germany) on Oct. 29, 2018, and the number is DSM 32939. The Parabacteroides goldsteinii is an obligate anaerobe that needs to be cultured in an anaerobic incubator at 37° C. for about 48 hours, wherein the culturing system contains 10% CO2, 10% H2, and 80% N2. The liquid culture medium of the Parabacteroides goldsteinii is NIH thioglycollate broth (TGC II) (purchased from BD, USA, No. 225710), and the solid culture medium is Anaerobic blood agar plate (Ana. BAP) (purchased from CREATIVE LIFESCIENCES, Taiwan). The Parabacteroides goldsteinii is stored in a −80° C. refrigerator for a long-term preservation, and the protective liquid is 25% glycerin. It does not need special cooling treatment and can be stored by freeze drying to stabilize its activity.
The Parabacteroides distasonis (hereinafter referred to as P. distasonis) used in the example of the present invention was purchased from American Type Culture Collection, and the number is ATCC 8503. YCFA medium was used for culturing, wherein the Parabacteroides distasonis was cultured in 50 mL YCFA at 37° C. in an anaerobic incubator for 24 hr. The cell suspension for oral administration was prepared by suspending the cultured bacterial cells in oxygen-free PBS with a final cell density of 1×109 CFU. 100 μL of the suspension solution was given daily.
The non-small cell lung cancer, NSCLC, used in the example of the present invention is Lewis lung cancer (LLC) cells (purchased from ATCC, and the number is ATCC®CRL 1642™). The LLC cells were maintained in Dulbecco's modified Eagle's medium, DMEM, (purchased from Gibco, USA) supplemented with 10% fetal bovine serum (purchased from Gibco, USA), 100 U/mL of penicillin, and 100 μg/mL of streptomycin, and were incubated at 37° C. in a humidified atmosphere containing 5% CO2.
Male C57BL/6J mice were randomly divided into the 4 groups (n=10 for each group), including the normal control group (CTL), the pathological control group (LLC), the experimental group (LLC+P. goldsteinii MTS01), and the comparison group (LLC+P. distasonis). The mice in the normal control group were treated with sterile drinking water and fed with PBS oral gavage once per day for 3 weeks; the mice in the pathological control group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1×106) intravenous injection via tail vein and fed with PBS by oral gavage once per day during the entire period of experiment; the mice in the experimental group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1×106) intravenous injection via tail vein and treated with Parabacteroides goldsteinii MTS01 (1×109 CFU) once per day by oral gavage during the entire period of experiment; the mice in the comparison group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1×106) intravenous injection via tail vein and treated with Parabacteroides distasonis (1×109 CFU) once per day by oral gavage during the entire period of experiment. The results of this example were represented by three independent experiments (n=10) and the results were shown in FIG. 1.
The results of the effect of the Parabacteroides goldsteinii MTS01 on increasing the survival rate of lung cancer mice were shown in FIG. 1. As showing in FIG. 1, after 21 days of intravenous injection of LLC cells, the survival rate of the mice in the pathological control group was 20%, and the survival rate of the mice in the experimental group was 50%, which was higher than that of the mice in the comparison group. The mice in the normal control were healthy and alive throughout the experiment. The results indicate that the Parabacteroides goldsteinii strain MTS01 of the present invention can increase the survival rate of mice with lung cancer.
Example 2
Effect of Parabacteroides goldsteinii MTS01 on Increasing the Mean Survival Time of Lung Cancer Mice
The experimental animals, the Parabacteroides goldsteinii, the Parabacteroides distasonis, and the type and the culturing method of the Lewis lung cancer were the same as those described in example 1.
Male C57BL/6J mice were randomly divided into the 4 groups (n=10 for each group), including the normal control group (CTL), the pathological control group (LLC), the experimental group (LLC+P. goldsteinii MTS01), and the comparison group (LLC+P. distasonis). The mice in the normal control group were treated with sterile drinking water and fed with PBS oral gavage once per day for 4 weeks; the mice in the pathological control group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1×106) intravenous injection via tail vein and fed with PBS by oral gavage once per day during the entire period of experiment; the mice in the experimental group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1×106) intravenous injection via tail vein and treated with Parabacteroides goldsteinii MTS01 (1×109 CFU) once per day by oral gavage during the entire period of experiment; the mice in the comparison group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1×106) intravenous injection via tail vein and treated with Parabacteroides distasonis (1×109 CFU) once per day by oral gavage during the entire period of experiment. The results of this example were represented by three independent experiments (n=10) and the results were shown in FIG. 2.
The results of the effect of the Parabacteroides goldsteinii MTS01 on increasing the mean survival time of lung cancer mice were shown in FIG. 2. As showing in FIG. 2, the mean survival time of the mice in the experimental group was 22.6 days, which was higher than that of the mice in the pathological control group (19.3 days) (P<0.01) and that of the mice in the comparison group. The mice in the normal control were healthy and alive throughout the experiment. The results indicate that the Parabacteroides goldsteinii strain MTS01 of the present invention can increase the mean survival time of mice with lung cancer.
Example 3
Effect of Parabacteroides goldsteinii MTS01 on Increasing the Body Weight of Lung Cancer Mice
The experimental animals, the Parabacteroides goldsteinii, the Parabacteroides distasonis, and the type and the culturing method of the Lewis lung cancer were the same as those described in example 1.
Male C57BL/6J mice were randomly divided into the 4 groups (n=10 for each group), including the normal control group (CTL), the pathological control group (LLC), the experimental group (LLC+P. goldsteinii MTS01), and the comparison group (LLC+P. distasonis). The mice in the normal control group were treated with sterile drinking water and fed with PBS oral gavage once per day for 4 weeks; the mice in the pathological control group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1×106) intravenous injection via tail vein and fed with PBS by oral gavage once per day during the entire period of experiment; the mice in the experimental group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1×106) intravenous injection via tail vein and treated with Parabacteroides goldsteinii MTS01 (1×109 CFU) once per day by oral gavage during the entire period of experiment; the mice in the comparison group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1×106) intravenous injection via tail vein and treated with Parabacteroides distasonis (1×109 CFU) once per day by oral gavage during the entire period of experiment.
In order to study the effect of the Parabacteroides distasonis MTS01 on improving the body weight loss in subjects caused by LLC, the body weight of each group of mice was monitored weekly for 4 weeks during the experiment. The final body weight at week 4 subtracted the starting weight at week 0 as the value of the body weight gain of each group of mice. The value of body weight gain was divided by the starting body weight and expressed as a percentage to calculate the body weight change rate of each group of mice. The results of the example were shown in FIG. 3.
The results of the effect of the Parabacteroides goldsteinii MTS01 on increasing the body weight of lung cancer mice were shown in FIG. 3. As showing in FIG. 3, the body weight gain of the mice in the pathological control group was significantly lower than that of the mice in the normal control group. However, compared with the pathological control group, the body weight gain of the mice in the experimental group mice was significantly increased with the simultaneously fed with the Parabacteroides goldsteinii MTS01 of the present invention, whereas the mice in the comparison group did not show this phenomenon. The results indicate that the Parabacteroides goldsteinii strain MTS01 of the present invention can effectively improve the body weight loss in the subjects caused by LLC.
Example 4
Effect of Parabacteroides goldsteinii MTS01 on Inhibiting the Growth of the Lung Tumor
The experimental animals, the Parabacteroides goldsteinii, the Parabacteroides distasonis, and the type and the culturing method of the Lewis lung cancer were the same as those described in example 1.
Male C57BL/6J mice were randomly divided into the 4 groups (n=10 for each group), including the normal control group (CTL), the pathological control group (LLC), the experimental group (LLC+P. goldsteinii MTS01), and the comparison group (LLC+P. distasonis). The mice in the normal control group were treated with sterile drinking water and fed with PBS oral gavage once per day for 3 weeks; the mice in the pathological control group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1×106) intravenous injection via tail vein and fed with PBS by oral gavage once per day during the entire period of experiment; the mice in the experimental group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1×106) intravenous injection via tail vein and treated with Parabacteroides goldsteinii MTS01 (1×109 CFU) once per day by oral gavage during the entire period of experiment; the mice in the comparison group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1×106) intravenous injection via tail vein and treated with Parabacteroides distasonis (1×109 CFU) once per day by oral gavage during the entire period of experiment. The results of this example were represented by three independent experiments (n=10).
After fed with the Parabacteroides distasonis MTS01 by oral gavage for 21 days, each group of mice was sacrificed, and the lungs were removed and the appearance of the lungs was observed. The results of the experiment were shown in FIG. 4.
The appearance results of the effect of the Parabacteroides goldsteinii MTS01 on inhibiting the growth of the lung tumor were shown in FIG. 4. As showing in FIG. 4, the solid tumors (as indicated by the arrows) were spotted on multiple sites in the group bearing with LLC. Compared with the pathological control group, the number of lung tumors in the mice of the experimental group was significantly reduced, while the comparison group did not show the phenomena. The results indicate that the Parabacteroides goldsteinii strain MTS01 of the present invention can inhibit the growth of lung tumor.
Next, the lung leaves of the mice in the normal control group (CTL), the pathological control group (LLC), and the experimental group (LLC+P. goldsteinii MTS01) were fixed in 10% neutral-buffered formalin, and then embedded in paraffin and thin sections with a thickness of 4 mm were prepared and stained with hematoxylin and eosin (H&E). Thereafter, the stained lungs were histologically examined using a slide scanner and the entire lung lobe was photographed (Olympus VS120). Representative images of whole slide scan and 500 μm or 250 μm optical zoom using H&E-stained lung sections. The results of the experiment were shown in FIG. 5.
The H&E stained results of the effect of the Parabacteroides goldsteinii MTS01 on inhibiting the growth of the lung tumor were shown in FIG. 5. As showing in FIG. 5, compared with the normal control group, the number of lung tumors in the mice of the pathological control group was significantly increased. However, compared with the pathological control group, the number of lung tumors in the mice of the experimental group was significantly reduced. The results indicate that the Parabacteroides goldsteinii strain MTS01 of the present invention can inhibit the growth of lung tumor.
Next, the lung tumors of the mice in the normal control group (CTL), the pathological control group (LLC), and the experimental group (LLC+Pg MTS01) were weighed, and the results of the experiment were shown in FIG. 6.
The data results of the effect of the Parabacteroides goldsteinii MTS01 on inhibiting the growth of the lung tumor were shown in FIG. 6. As showing in FIG. 6, compared with the normal control group, the lung tumor weight of the mice in the pathological control group was significantly increased. However, compared with the pathological control group, the lung tumor weight of the mice in the experimental group was significantly reduced. The results indicate that the Parabacteroides goldsteinii MTS01 of the present invention can inhibit the growth of the tumor growth in the mouse model with lung tumors.
Example 5
In Vivo Effect of Parabacteroides goldsteinii MTS01 on Inhibiting Lung Cancer at Different Time Points
The experimental animals, the Parabacteroides goldsteinii, the Parabacteroides distasonis, and the type and the culturing method of the Lewis lung cancer were the same as those described in example 1.
Male C57BL/6J mice were randomly divided into the 3 groups (n=10 for each group), including the normal control group (CTL), the pathological control group (LLC), and the experimental group (LLC+Pg MTS01). Wherein, the mice in the normal control group were treated with sterile drinking water and fed with PBS oral gavage once per day; the mice in the pathological control group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1×106) intravenous injection via tail vein and fed with PBS by oral gavage once per day during the entire period of experiment; the mice in the experimental group were treated with Neomycin (1 g/L) in drinking water for 7 days, followed by LLC cells (1×106) intravenous injection via tail vein and treated with Parabacteroides goldsteinii MTS01 (1×109 CFU) once per day by oral gavage during the entire period of experiment. The results of this example were represented by three independent experiments (n=10).
At the day 0, 7, 14, and 21 after implantation of LLC cells, the mice of each group were anesthetized with isoflurane and intraperitoneally injected with firefly D-luciferin (15 mg/mL in PBS; Gold Biotechnology), and then were imaged with a cooled charge-coupled device (CCD) camera (IVIS; PerkinElmer) after 7 minutes. In vivo imaging was performed with IVIS Lumina XR Imaging system (PerkinElmer). The luciferin dose was 150 mg/kg. The results of the example were shown in FIG. 7 to FIG. 10. The scale indicates luminescent intensity in terms of radiant efficiency.
The bioluminescence imaging results of in vivo effect of Parabacteroides goldsteinii MTS01 on inhibiting lung cancer after LLC cells implanted on the 7th day were shown in FIG. 7. As showing in FIG. 7, compared with the normal control group, the luminescent intensity measured from the mice in the pathological control group was significantly increased. However, compared with the pathological control group, the luminescent intensity measured from the mice in the experimental group was significantly reduced. The results indicate that the Parabacteroides goldsteinii MTS01 of the present invention has an effect of inhibiting lung cancer after LLC cells implanted on the 7th day in vivo.
The bioluminescence imaging results of in vivo effect of Parabacteroides goldsteinii MTS01 on inhibiting lung cancer after LLC cells implanted on the 14th day were shown in FIG. 8. As showing in FIG. 8, compared with the normal control group, the luminescent intensity measured from the mice in the pathological control group was significantly increased. However, compared with the pathological control group, the luminescent intensity measured from the mice in the experimental group was significantly reduced. The results indicate that the Parabacteroides goldsteinii MTS01 of the present invention has an effect of inhibiting lung cancer after LLC cells implanted on the 14th day in vivo.
The bioluminescence imaging results of in vivo effect of Parabacteroides goldsteinii MTS01 on inhibiting lung cancer after LLC cells implanted on the 21st day were shown in FIG. 9. As showing in FIG. 9, compared with the normal control group, the luminescent intensity measured from the mice in the pathological control group was significantly increased. However, compared with the pathological control group, the luminescent intensity measured from the mice in the experimental group was significantly reduced. The results indicate that the Parabacteroides goldsteinii MTS01 of the present invention has an effect of inhibiting lung cancer after LLC cells implanted on the 21st day in vivo.
The results of in vivo effect of the Parabacteroides goldsteinii MTS01 on inhibiting lung cancer at different time points were shown in FIG. 10. As showing in FIG. 10, compared with the normal control group, the luminescent intensity measured from the mice in the pathological control group increased significantly as the time of LLC cells implantation. However, compared with the pathological control group, though the luminescent intensity measured from the mice in the experimental group increased as the time of LLC cells implantation, but the increase range was significantly reduced. The results indicate that the Parabacteroides goldsteinii MTS01 of the present invention has an effect of inhibiting lung cancer at different time points in vivo.
In summary, the effect of the Parabacteroides goldsteinii of the present invention is that the effect of treating lung cancer which is achieved by increasing the survival rate, the mean survival time, and the body weight of the subjects with lung cancer, and inhibiting the growth of the lung tumor.
The above description is by way of example only and not as a limitation. Any equivalent modifications or alterations to the spirit and scope of the invention are intended to be included in the scope of the appended claims.

Claims (12)

What is claimed is:
1. A method of treating a lung cancer, comprising administering to a subject in need thereof a composition comprising an effective amount of a Parabacteroides goldsteinii; wherein the Parabacteroides goldsteinii is Parabacteroides goldsteinii DSM32939.
2. The method according to claim 1, wherein the composition further comprises a metabolite of the Parabacteroides goldsteinii.
3. The method according to claim 1, wherein the Parabacteroides goldsteinii is a live bacterium.
4. The method according to claim 1, wherein the effective amount of the Parabacteroides goldsteinii is at least 1×109 CFUs per day.
5. The method according to claim 1, wherein the lung cancer is a non-small cell lung cancer.
6. The method according to claim 5, wherein the non-small cell lung cancer is a Lewis lung carcinoma.
7. The method according to claim 1, wherein the composition increases a survival rate, a mean survival time and a body weight of the subject with the lung cancer, and inhibits a growth of a lung tumor.
8. The method according to claim 7, wherein inhibiting comprises inhibiting the growth of the lung tumor at different time points.
9. The method according to claim 1, wherein the composition further comprises other bacteria.
10. The method according to claim 1, wherein the composition is a pharmaceutical composition or a food product.
11. The method according to claim 10, wherein the composition further comprises a pharmaceutically acceptable excipient, carrier, adjuvant, or food additive.
12. The method according to claim 1, wherein the composition is in the form of a spray, a solution, a semi-solid state, a solid state, a gelatin capsule, a soft capsule, a tablet, an oral strip, a chewing gum or a freeze-dried powder preparation.
US16/667,950 2018-10-31 2019-10-30 Method of treating lung cancer using Parabacteroides goldsteinii Active 2040-01-28 US11116803B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/667,950 US11116803B2 (en) 2018-10-31 2019-10-30 Method of treating lung cancer using Parabacteroides goldsteinii

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862753112P 2018-10-31 2018-10-31
TW108138285A TWI733222B (en) 2018-10-31 2019-10-23 Use of parabacteroides goldsteinii for treating lung cancer
TW108138285 2019-10-23
US16/667,950 US11116803B2 (en) 2018-10-31 2019-10-30 Method of treating lung cancer using Parabacteroides goldsteinii

Publications (2)

Publication Number Publication Date
US20200129568A1 US20200129568A1 (en) 2020-04-30
US11116803B2 true US11116803B2 (en) 2021-09-14

Family

ID=70327529

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/667,950 Active 2040-01-28 US11116803B2 (en) 2018-10-31 2019-10-30 Method of treating lung cancer using Parabacteroides goldsteinii

Country Status (2)

Country Link
US (1) US11116803B2 (en)
CN (1) CN111110702B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI636788B (en) * 2017-08-28 2018-10-01 長庚生物科技股份有限公司 Use of parabacteroides goldsteinii to treat fatty liver disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112363A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Methods of treating cancer using parabacteroides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41060B1 (en) * 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112363A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Methods of treating cancer using parabacteroides

Also Published As

Publication number Publication date
US20200129568A1 (en) 2020-04-30
CN111110702B (en) 2021-09-17
CN111110702A (en) 2020-05-08

Similar Documents

Publication Publication Date Title
US11116806B2 (en) Composite probiotic lactic acid bacteria powder and preparation method and use thereof
US6562336B2 (en) Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
JP7414328B2 (en) Lactobacillus acidophilus KBL409 strain and its uses
KR20220131844A (en) Lactobacillus plantarum GB104 strain and composition for preventing or treating cancer comprising the same
KR20160032722A (en) Composition comprising extracellular vesicles derived from fermented food, and use thereof
CN111560331B (en) Lactobacillus paracasei and application thereof
JP5046684B2 (en) Intestinal barrier function recovery agent and intestinal barrier permeability enhancement inhibitor
EP2110133B1 (en) Prophylactic and/or therapeutic agent for functional gastrointestinal disorders
KR20190143336A (en) A composition for improving liver function comprising genus Leuconostoc
KR102173168B1 (en) A composition for improving intestine function comprising genus Leuconostoc
US11116803B2 (en) Method of treating lung cancer using Parabacteroides goldsteinii
KR101238836B1 (en) Phamaceutical or food composition for treating or preventing obesity disease comprising a mixture of lactic acid bacteria
KR102651098B1 (en) Novel Lactobacillus reuteri strain and the use thereof
KR20180110848A (en) A novel Lactobacillus reuteri BM36301 and a Probiotic Benefits of the same
US20250325607A1 (en) Composition for preventing, treating, or improving metabolic diseases comprising lactobacillus plantarum nchbl-004 strain or culture medium thereof
KR102639561B1 (en) Composition for preventing, treating or improving metabolic disease including obesity, diabetes or fatty liver using Lactobacillus plantarum NCHBL-004 strain or culture medium thereof
EP3837993A1 (en) Composition for improving intestinal function comprising leuconostoc sp. strain
TWI733222B (en) Use of parabacteroides goldsteinii for treating lung cancer
EP3837992A1 (en) Composition comprising leuconostoc sp. strain for improvement of liver function
KR102681848B1 (en) A pharmaceutical composition for preventing or treating liver fibrosis containing Lactobacillus delbrueckii subsp. lactis CKDB001
US11911421B2 (en) Probiotic composition including lactic acid bacterial strains and use thereof
KR102264188B1 (en) Lactobacillus sakei MBEL1397 (KCTC14037BP) from danggui kimchi and composition with hypoglycemic effects thereof
US20230302065A1 (en) Composition with lactobacillus paracasei and a method to treat nasopharyngeal carcinoma through pyroptosis or cell cycle arrest
US20240335488A1 (en) Novel lactobacillus helveticus ua881 strain and probiotic composition for improving intestinal permeability and metabolic disorders
Naz et al. Summary of Probiotic Potential of the Kefir for the Prevention and Alleviation of Functional GI Diseases

Legal Events

Date Code Title Description
AS Assignment

Owner name: MULTISTARS BIOTECHNOLOGY COMPANY LIMITED, TAIWAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WU, PO-I;CHANG, CHIH-JUNG;TSAI, YU-LING;REEL/FRAME:050872/0775

Effective date: 20191028

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4